HilleVax Q1 2023 Earnings Report $1.84 -0.04 (-1.87%) As of 02/21/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast HilleVax EPS ResultsActual EPS-$0.71Consensus EPS -$0.96Beat/MissBeat by +$0.25One Year Ago EPSN/AHilleVax Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHilleVax Announcement DetailsQuarterQ1 2023Date5/12/2023TimeN/AConference Call ResourcesPress ReleaseHLVX Earnings HistoryPowered by HilleVax Earnings HeadlinesHillevax CEO Robert Hershberg sells $48,661 in stockFebruary 12, 2025 | msn.comHillevax CFO Shane Maltbie sells $15,116 in stockFebruary 12, 2025 | msn.comMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.February 22, 2025 | Colonial Metals (Ad)HilleVax, Inc. Announces Workforce Reduction and Leadership ChangesDecember 5, 2024 | tipranks.comCautious Hold Rating on HilleVax, Inc: Balancing Strong Cash Reserves with Strategic UncertaintyNovember 12, 2024 | markets.businessinsider.comHilleVax Reports Q3 Financial Results Amid Strategic PlanningNovember 9, 2024 | markets.businessinsider.comSee More HilleVax Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HilleVax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HilleVax and other key companies, straight to your email. Email Address About HilleVaxHilleVax (NASDAQ:HLVX), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.View HilleVax ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
